Adipotide
Prohibitin-Targeting Peptidomimetic · Experimental Anti-Obesity
Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.
Overview
Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.
CKGGRAKDC ligand homes to prohibitin/annexin A2 on white-fat endothelium; linked D-(KLAKLAK)2 disrupts mitochondrial membranes post-internalization, triggering localized endothelial apoptosis and adipocyte loss.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Selective white adipose tissue vascular targeting produced 7-15% body-weight loss over 4 weeks in obese macaques.
Improved insulin response (reduced insulin AUC) following fat-mass reduction in primates.
Weight loss without primary appetite suppression; peripheral vascular approach.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Chimeric peptidomimetic
- Typical dose
- 0.43 mg/kg
- Frequency
- Once daily
- Cycle length
- 28 days
- Storage
- Lyophilized: -20°C freezer. Reconstituted: 2-8°C refrigerated
Molecular data
- Type
- Chimeric peptidomimetic
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Primate Research Replication | SubQ | 0.43 mg/kg | Once daily |
| Dose-Finding (Research) | SubQ | 0.10-0.75 mg/kg | Once daily (escalating tiers) |
Interactions
Potential additive dehydration/GI effects; monitor renal function.
Overlapping weight-loss effects; monitor kidney function, volume status, electrolytes.
No clinical data on co-administration; mechanisms differ.
No published data on combined use or pharmacodynamic interaction.
No known direct interaction; distinct mechanisms and targets.
Metabolic effects may confound body-composition endpoints.
Theoretical vascular/pressor effects; stagger dosing, monitor BP and hydration.
Adipotide shows dose-dependent proximal tubule injury; avoid additional renal insults.
Quality checklist
- ✓Intact lyophilized cake - white, uniform indicates proper lyophilization
- ✓Clear solution - fully dissolved, particle-free after reconstitution
- !Minor clumping may form from shipping; should dissolve with gentle swirl
- ×Collapsed/moist cake suggests temperature excursion; do not use without QC
- ×Cloudiness/precipitate indicates degradation or contamination—discard
What to expect
Safety
- Mild creatinine elevation
- Electrolyte shifts
- Dose-dependent proximal tubule changes (reversible in primates)
- Sustained creatinine elevation or oliguria
- Progressive electrolyte abnormalities
- Severe injection-site reactions or systemic symptoms
- Unexpected toxicity
- Pregnancy/lactation (not studied)
- Dehydration
- Concurrent nephrotoxic medications
FAQ
How does Adipotide's weight loss mechanism differ from semaglutide?
Adipotide targets adipose tissue vascular endothelium directly, causing localized endothelial apoptosis and adipocyte loss via a peripheral vascular mechanism. Semaglutide suppresses appetite centrally via GLP-1 receptors. Adipotide achieves weight loss without appetite suppression, making it mechanistically distinct from appetite suppressants.
What kidney safety concerns halted Adipotide's Phase 1 development?
Phase 1 trials showed dose-dependent mild creatinine elevation and reversible proximal tubule changes in kidney tissue. Although these effects reversed in primates, the kidney safety signals were considered significant enough to halt further clinical development. This remains a major concern for any consideration of Adipotide use.
How much weight can Adipotide actually produce?
In obese rhesus macaques, 0.43mg/kg SC daily for 28 days produced 7.4-14.7% body weight loss with improved insulin sensitivity. However, primate studies don't guarantee equivalent human efficacy, and the kidney safety signals prevented human Phase 2 trials from determining real-world dose-response in people.
Can I combine Adipotide with semaglutide for enhanced weight loss?
No combination data exists, and stacking has theoretical risks. Both would drive rapid weight loss and dehydration. Adipotide shows dose-dependent kidney effects, and semaglutide users already face dehydration/GI issues. Combined use requires careful monitoring of renal function, electrolytes, and hydration status, best avoided without specialist supervision.